Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 308

1.

Comprehensive molecular landscape in patients older than 80 years old diagnosed with acute myeloid leukemia: A study of the French Hauts-de-France AML observatory.

Renaud L, Nibourel O, Marceau-Renaut A, Gruson B, Cambier N, Lionne-Huyghe P, Choufi B, Rodriguez C, Frimat C, Plantier I, Stalnikiewicz L, Bemba M, Berthon C, Marolleau JP, Quesnel B, Preudhomme C, Duployez N.

Am J Hematol. 2018 Oct 25. doi: 10.1002/ajh.25328. [Epub ahead of print] No abstract available.

PMID:
30358899
2.

A 17-gene-expression profile to improve prognosis prediction in childhood acute myeloid leukemia.

Duployez N, Preudhomme C, Cheok M.

Oncotarget. 2018 Sep 21;9(74):33869-33870. doi: 10.18632/oncotarget.26116. eCollection 2018 Sep 21. No abstract available.

3.

The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia.

Duployez N, Marceau-Renaut A, Villenet C, Petit A, Rousseau A, Ng SWK, Paquet A, Gonzales F, Barthélémy A, Leprêtre F, Pottier N, Nelken B, Michel G, Baruchel A, Bertrand Y, Leverger G, Lapillonne H, Figeac M, Dick JE, Wang JCY, Preudhomme C, Cheok M.

Leukemia. 2018 Aug 8. doi: 10.1038/s41375-018-0227-5. [Epub ahead of print]

PMID:
30089916
4.

Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase 3 ALFA-0701 trial.

Lambert J, Pautas C, Terré C, Raffoux E, Turlure P, Caillot D, Legrand O, Thomas X, Gardin C, Gogat-Marchant K, Rubin SD, Benner RJ, Bousset P, Preudhomme C, Chevret S, Dombret H, Castaigne S.

Haematologica. 2018 Aug 3. pii: haematol.2018.188888. doi: 10.3324/haematol.2018.188888. [Epub ahead of print]

5.

Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A.

Kelaidi C, Braun T, Arana R, Marceau-Renaut A, Lazarian G, Soret J, Cereja S, Letestu R, Eclache V, Lusina D, Baran-Marszak F, Ades L, Preudhomme C, Martin A, Fenaux P, Gardin C.

Leuk Res. 2018 Aug;71:67-74. doi: 10.1016/j.leukres.2018.05.007. Epub 2018 May 29.

PMID:
30025278
6.

Polycomb repressive complex 2 haploinsufficiency identifies a high-risk subgroup of pediatric acute myeloid leukemia.

Bond J, Labis E, Marceau-Renaut A, Duployez N, Labopin M, Hypolite G, Michel G, Ducassou S, Boutroux H, Nelken B, Bertrand Y, Baruchel A, Petit A, Asnafi V, Leverger G, Preudhomme C, Macintyre E, Lapillonne H.

Leukemia. 2018 Aug;32(8):1878-1882. doi: 10.1038/s41375-018-0187-9. Epub 2018 Jun 27. No abstract available.

PMID:
29950694
7.

Correction: Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study.

Marino P, Touzani R, Perrier L, Rouleau E, Kossi DS, Zhaomin Z, Charrier N, Goardon N, Preudhomme C, Durand-Zaleski I, Borget I, Baffert S; NGSEco Group:.

Eur J Hum Genet. 2018 Sep;26(9):1396-1397. doi: 10.1038/s41431-018-0194-3.

8.

A novel type of NPM1 mutation characterized by multiple internal tandem repeats in a case of cytogenetically normal acute myeloid leukemia.

Duployez N, Chebrek L, Helevaut N, Fournier E, Bemba M, Caillault A, Geffroy S, Preudhomme C.

Haematologica. 2018 Jun 14. pii: haematol.2018.190959. doi: 10.3324/haematol.2018.190959. [Epub ahead of print] No abstract available.

9.

NPM1 mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents.

Prata PH, Bally C, Prebet T, Recher C, Venton G, Thomas X, Raffoux E, Pigneux A, Cluzeau T, Desoutter J, Gay J, Preudhomme C, Fenaux P, Adès L.

Haematologica. 2018 Oct;103(10):e455-e457. doi: 10.3324/haematol.2018.189886. Epub 2018 May 10. No abstract available.

10.

Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia.

Renneville A, Attias P, Thomas X, Bally C, Hayette S, Farhat H, Eclache V, Marceau-Renaut A, Cassinat B, Feuillard J, Terré C, Delabesse E, Park S, Lejeune J, Chevret S, Adès L, Preudhomme C, Fenaux P.

Leukemia. 2018 Sep;32(9):2066-2069. doi: 10.1038/s41375-018-0137-6. Epub 2018 Apr 18. No abstract available.

PMID:
29740159
11.

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.

Duchmann M, Yalniz FF, Sanna A, Sallman D, Coombs CC, Renneville A, Kosmider O, Braun T, Platzbecker U, Willems L, Adès L, Fontenay M, Rampal R, Padron E, Droin N, Preudhomme C, Santini V, Patnaik MM, Fenaux P, Solary E, Itzykson R.

EBioMedicine. 2018 May;31:174-181. doi: 10.1016/j.ebiom.2018.04.018. Epub 2018 Apr 25.

12.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

Donadieu J, Lamant M, Fieschi C, de Fontbrune FS, Caye A, Ouachee M, Beaupain B, Bustamante J, Poirel HA, Isidor B, Van Den Neste E, Neel A, Nimubona S, Toutain F, Barlogis V, Schleinitz N, Leblanc T, Rohrlich P, Suarez F, Ranta D, Chahla WA, Bruno B, Terriou L, Francois S, Lioure B, Ahle G, Bachelerie F, Preudhomme C, Delabesse E, Cave H, Bellanné-Chantelot C, Pasquet M; French GATA2 study group.

Haematologica. 2018 Aug;103(8):1278-1287. doi: 10.3324/haematol.2017.181909. Epub 2018 May 3.

13.

Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia.

Itzykson R, Duployez N, Fasan A, Decool G, Marceau-Renaut A, Meggendorfer M, Jourdan E, Petit A, Lapillonne H, Micol JB, Cornillet-Lefebvre P, Ifrah N, Leverger G, Dombret H, Boissel N, Haferlach T, Preudhomme C.

Blood. 2018 Jul 12;132(2):187-196. doi: 10.1182/blood-2018-03-837781. Epub 2018 Apr 24.

PMID:
29692343
14.

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up.

Boyer T, Gonzales F, Plesa A, Peyrouze P, Barthelemy A, Guihard S, Quesnel B, Roumier C, Preudhomme C, Cheok M.

J Vis Exp. 2018 Mar 26;(133). doi: 10.3791/56976.

PMID:
29630051
15.

Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia.

Ali A, Penneroux J, Dal Bello R Jr, Massé A, Quentin S, Unnikrishnan A, Hernandez L, Raffoux E, Ben Abdelali R, Renneville A, Preudhomme C, Pimanda J, Dombret H, Soulier J, Fenaux P, Clappier E, Adès L, Puissant A, Itzykson R.

Leukemia. 2018 Aug;32(8):1856-1860. doi: 10.1038/s41375-018-0076-2. Epub 2018 Feb 26. No abstract available.

PMID:
29535430
16.

Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations.

Willekens C, Renneville A, Broutin S, Saada V, Micol JB, Delahousse J, Poinsignon V, Bories C, Berthon C, Itzykson R, Boissel N, Quivoron C, Terroir-Cassou-Mounat M, Bosq J, Preudhomme C, Paci A, Penard-Lacronique V, De Botton S.

Leukemia. 2018 Sep;32(9):2008-2081. doi: 10.1038/s41375-018-0056-6. Epub 2018 Feb 26. No abstract available.

PMID:
29479068
17.

Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group.

Ferret Y, Boissel N, Helevaut N, Madic J, Nibourel O, Marceau-Renaut A, Bucci M, Geffroy S, Celli-Lebras K, Castaigne S, Thomas X, Terré C, Dombret H, Preudhomme C, Renneville A.

Haematologica. 2018 May;103(5):822-829. doi: 10.3324/haematol.2017.183525. Epub 2018 Feb 22.

18.

SNP-array lesions in core binding factor acute myeloid leukemia.

Duployez N, Boudry-Labis E, Roumier C, Boissel N, Petit A, Geffroy S, Helevaut N, Celli-Lebras K, Terré C, Fenneteau O, Cuccuini W, Luquet I, Lapillonne H, Lacombe C, Cornillet P, Ifrah N, Dombret H, Leverger G, Jourdan E, Preudhomme C.

Oncotarget. 2018 Jan 8;9(5):6478-6489. doi: 10.18632/oncotarget.24031. eCollection 2018 Jan 19.

19.

Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study.

Marino P, Touzani R, Perrier L, Rouleau E, Kossi DS, Zhaomin Z, Charrier N, Goardon N, Preudhomme C, Durand-Zaleski I, Borget I, Baffert S; NGSEco Group: .

Eur J Hum Genet. 2018 Mar;26(3):314-323. doi: 10.1038/s41431-017-0081-3. Epub 2018 Jan 24. Erratum in: Eur J Hum Genet. 2018 Jun 15;:.

PMID:
29367707
20.

Role of IRF4 in resistance to immunomodulatory (IMid) compounds® in Waldenström's macroglobulinemia.

Bertrand E, Jouy N, Manier S, Fouquet G, Guidez S, Boyle E, Noel S, Tomowiak C, Herbaux C, Schraen S, Preudhomme C, Quesnel B, Poulain S, Leleu X.

Oncotarget. 2017 Dec 4;8(68):112917-112927. doi: 10.18632/oncotarget.22872. eCollection 2017 Dec 22.

21.

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.

Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills RK, Hourigan CS, Jorgensen JL, Kern W, Lacombe F, Maurillo L, Preudhomme C, van der Reijden BA, Thiede C, Venditti A, Vyas P, Wood BL, Walter RB, Döhner K, Roboz GJ, Ossenkoppele GJ.

Blood. 2018 Mar 22;131(12):1275-1291. doi: 10.1182/blood-2017-09-801498. Epub 2018 Jan 12. Review.

PMID:
29330221
22.

Acute megakaryoblastic leukemia (excluding Down syndrome) remains an acute myeloid subgroup with inferior outcome in the French ELAM02 trial.

Teyssier AC, Lapillonne H, Pasquet M, Ballerini P, Baruchel A, Ducassou S, Fenneteau O, Petit A, Cuccuini W, Ragu C, Preudhomme C, Mercher T, Sirvent N, Leverger G.

Pediatr Hematol Oncol. 2017 Nov;34(8):425-427. doi: 10.1080/08880018.2017.1414905. Epub 2018 Jan 5.

PMID:
29303660
23.

Reactive oxygen species levels control NF-κB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes.

Meunier M, Ancelet S, Lefebvre C, Arnaud J, Garrel C, Pezet M, Wang Y, Faure P, Szymanski G, Duployez N, Preudhomme C, Biard D, Polack B, Cahn JY, Moulis JM, Park S.

Oncotarget. 2017 Nov 6;8(62):105510-105524. doi: 10.18632/oncotarget.22299. eCollection 2017 Dec 1.

24.

Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia.

Lacombe F, Campos L, Allou K, Arnoulet C, Delabarthe A, Dumezy F, Feuillard J, Geneviève F, Guérin E, Guy J, Jouault H, Lepelley P, Maynadié M, Solly F, Ballon OW, Preudhomme C, Baruchel A, Dombret H, Ifrah N, Béné MC; Groupe d'Etude Immunologique des Leucémies (GEIL).

Hematol Oncol. 2018 Apr;36(2):422-428. doi: 10.1002/hon.2488. Epub 2017 Dec 7.

PMID:
29218734
25.

Down syndrome-like acute megakaryoblastic leukemia in a patient with Cornelia de Lange syndrome.

Vial Y, Lachenaud J, Verloes A, Besnard M, Fenneteau O, Lainey E, Marceau-Renaut A, Preudhomme C, Baruchel A, Cavé H, Drunat S.

Haematologica. 2018 Jun;103(6):e274-e276. doi: 10.3324/haematol.2017.178590. Epub 2017 Dec 7. No abstract available.

26.

Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia.

Petit A, Trinquand A, Chevret S, Ballerini P, Cayuela JM, Grardel N, Touzart A, Brethon B, Lapillonne H, Schmitt C, Thouvenin S, Michel G, Preudhomme C, Soulier J, Landman-Parker J, Leverger G, Macintyre E, Baruchel A, Asnafi V; French Acute Lymphoblastic Leukemia Study Group (FRALLE).

Blood. 2018 Jan 18;131(3):289-300. doi: 10.1182/blood-2017-04-778829. Epub 2017 Oct 19.

PMID:
29051182
27.

Detection of a new heterozygous germline ETV6 mutation in a case with hyperdiploid acute lymphoblastic leukemia.

Duployez N, Abou Chahla W, Lejeune S, Marceau-Renaut A, Letizia G, Boyer T, Geffroy S, Peyrouze P, Grardel N, Nelken B, Michel G, Bertrand Y, Preudhomme C.

Eur J Haematol. 2018 Jan;100(1):104-107. doi: 10.1111/ejh.12981. Epub 2017 Nov 9. Review.

PMID:
29034503
28.

TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia.

Poulain S, Roumier C, Bertrand E, Renneville A, Caillault-Venet A, Doye E, Geffroy S, Sebda S, Nibourel O, Nudel M, Herbaux C, Renaud L, Tomowiak C, Guidez S, Tricot S, Roche-Lestienne C, Quesnel B, Preudhomme C, Leleu X.

Clin Cancer Res. 2017 Oct 15;23(20):6325-6335. doi: 10.1158/1078-0432.CCR-17-0007. Epub 2017 Jul 28.

29.

Familial CEBPA-mutated acute myeloid leukemia.

Tawana K, Rio-Machin A, Preudhomme C, Fitzgibbon J.

Semin Hematol. 2017 Apr;54(2):87-93. doi: 10.1053/j.seminhematol.2017.04.001. Epub 2017 Apr 7. Review.

PMID:
28637622
30.

ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia.

Micol JB, Pastore A, Inoue D, Duployez N, Kim E, Lee SC, Durham BH, Chung YR, Cho H, Zhang XJ, Yoshimi A, Krivtsov A, Koche R, Solary E, Sinha A, Preudhomme C, Abdel-Wahab O.

Nat Commun. 2017 May 18;8:15429. doi: 10.1038/ncomms15429.

31.

Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission.

Thomas X, de Botton S, Chevret S, Caillot D, Raffoux E, Lemasle E, Marolleau JP, Berthon C, Pigneux A, Vey N, Reman O, Simon M, Recher C, Cahn JY, Hermine O, Castaigne S, Celli-Lebras K, Ifrah N, Preudhomme C, Terré C, Dombret H.

J Clin Oncol. 2017 Apr 10;35(11):1223-1230. doi: 10.1200/JCO.2016.70.4551. Epub 2017 Feb 21.

PMID:
28221862
32.

TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML.

Mohamed AM, Balsat M, Koering C, Maucort-Boulch D, Boissel N, Payen-Gay L, Cheok M, Mortada H, Auboeuf D, Pinatel C, El-Hamri M, Tigaud I, Hayette S, Dumontet C, Cros E, Flandrin-Gresta P, Nibourel O, Preudhomme C, Thomas X, Nicolini FE, Solly F, Guyotat D, Campos L, Michallet M, Ceraulo A, Mortreux F, Wattel E.

Leuk Res. 2017 May;56:21-28. doi: 10.1016/j.leukres.2017.01.012. Epub 2017 Jan 16.

PMID:
28167452
33.

Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML.

Duléry R, Nibourel O, Gauthier J, Elsermans V, Behal H, Coiteux V, Magro L, Renneville A, Marceau A, Boyer T, Quesnel B, Preudhomme C, Duhamel A, Yakoub-Agha I.

Bone Marrow Transplant. 2017 Apr;52(4):539-543. doi: 10.1038/bmt.2016.318. Epub 2017 Jan 9.

PMID:
28067876
34.

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.

Balsat M, Renneville A, Thomas X, de Botton S, Caillot D, Marceau A, Lemasle E, Marolleau JP, Nibourel O, Berthon C, Raffoux E, Pigneux A, Rodriguez C, Vey N, Cayuela JM, Hayette S, Braun T, Coudé MM, Terre C, Celli-Lebras K, Dombret H, Preudhomme C, Boissel N.

J Clin Oncol. 2017 Jan 10;35(2):185-193. Epub 2016 Nov 14.

PMID:
28056203
35.

High-throughput sequencing in acute lymphoblastic leukemia: Follow-up of minimal residual disease and emergence of new clones.

Salson M, Giraud M, Caillault A, Grardel N, Duployez N, Ferret Y, Duez M, Herbert R, Rocher T, Sebda S, Quief S, Villenet C, Figeac M, Preudhomme C.

Leuk Res. 2017 Feb;53:1-7. doi: 10.1016/j.leukres.2016.11.009. Epub 2016 Nov 21.

PMID:
27930944
36.

A 17-gene stemness score for rapid determination of risk in acute leukaemia.

Ng SW, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N, Arruda A, Popescu A, Gupta V, Schimmer AD, Schuh AC, Yee KW, Bullinger L, Herold T, Görlich D, Büchner T, Hiddemann W, Berdel WE, Wörmann B, Cheok M, Preudhomme C, Dombret H, Metzeler K, Buske C, Löwenberg B, Valk PJ, Zandstra PW, Minden MD, Dick JE, Wang JC.

Nature. 2016 Dec 15;540(7633):433-437. doi: 10.1038/nature20598. Epub 2016 Dec 7.

PMID:
27926740
37.

Myelodysplastic syndromes and acute leukemia with genetic predispositions: a new challenge for hematologists.

Duployez N, Lejeune S, Renneville A, Preudhomme C.

Expert Rev Hematol. 2016 Dec;9(12):1189-1202. Epub 2016 Nov 21. Review.

PMID:
27819178
38.

Copy-number analysis identified new prognostic marker in acute myeloid leukemia.

Nibourel O, Guihard S, Roumier C, Pottier N, Terre C, Paquet A, Peyrouze P, Geffroy S, Quentin S, Alberdi A, Abdelali RB, Renneville A, Demay C, Celli-Lebras K, Barbry P, Quesnel B, Castaigne S, Dombret H, Soulier J, Preudhomme C, Cheok MH.

Leukemia. 2017 Mar;31(3):555-564. doi: 10.1038/leu.2016.265. Epub 2016 Sep 30.

PMID:
27686867
39.

Absence of CALR mutations in JAK2-negative polycythemia.

Chauveau A, Nibourel O, Tondeur S, Paz DL, Mansier O, Paul F, Wemeau M, Preudhomme C, Lippert E, Ugo V; French Intergroup of Myeloproliferative Neoplasms.

Haematologica. 2017 Jan;102(1):e15-e16. doi: 10.3324/haematol.2016.154799. Epub 2016 Oct 6. No abstract available.

40.

LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis.

Ceroi A, Masson D, Roggy A, Roumier C, Chagué C, Gauthier T, Philippe L, Lamarthée B, Angelot-Delettre F, Bonnefoy F, Perruche S, Biichle S, Preudhomme C, Macintyre E, Lagrost L, Garnache-Ottou F, Saas P.

Blood. 2016 Dec 8;128(23):2694-2707. Epub 2016 Oct 4.

41.

Minimal Residual Disease assessment of IDH1/2 mutations in Acute Myeloid Leukemia by LNA-RQ-PCR.

Abdelhamid E, Besbes S, Renneville A, Nibourel O, Helevaut N, Preudhomme C, Soua Z.

Tunis Med. 2016 Mar;94(3):190-7.

42.

Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia.

Boyer T, Guihard S, Roumier C, Peyrouze P, Gonzales F, Berthon C, Quesnel B, Preudhomme C, Behal H, Duhamel A, Roche-Lestienne C, Cheok M.

Oncotarget. 2016 Sep 20;7(38):62377-62385. doi: 10.18632/oncotarget.11481.

43.

BACH2 promotes indolent clinical presentation in Waldenström macroglobulinemia.

Herbaux C, Bertrand E, Marot G, Roumier C, Poret N, Soenen V, Nibourel O, Roche-Lestienne C, Broucqsault N, Galiègue-Zouitina S, Boyle EM, Fouquet G, Renneville A, Tricot S, Morschhauser F, Preudhomme C, Quesnel B, Poulain S, Leleu X.

Oncotarget. 2016 Jun 7;8(34):57451-57459. doi: 10.18632/oncotarget.9917. eCollection 2017 Aug 22.

44.

Microparticle phenotypes are associated with driver mutations and distinct thrombotic risks in essential thrombocythemia.

Charpentier A, Lebreton A, Rauch A, Bauters A, Trillot N, Nibourel O, Tintillier V, Wemeau M, Demory JL, Preudhomme C, Jude B, Lecompte T, Cambier N, Susen S.

Haematologica. 2016 Sep;101(9):e365-8. doi: 10.3324/haematol.2016.144279. Epub 2016 May 31. No abstract available.

45.

A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.

Thépot S, Ben Abdelali R, Chevret S, Renneville A, Beyne-Rauzy O, Prébet T, Park S, Stamatoullas A, Guerci-Bresler A, Cheze S, Tertian G, Choufi B, Legros L, Bastié JN, Delaunay J, Chaury MP, Sanhes L, Wattel E, Dreyfus F, Vey N, Chermat F, Preudhomme C, Fenaux P, Gardin C; Groupe Francophone des Myélodysplasies (GFM).

Haematologica. 2016 Aug;101(8):918-25. doi: 10.3324/haematol.2015.140988. Epub 2016 May 26.

46.

Haematological spectrum and genotype-phenotype correlations in nine unrelated families with RUNX1 mutations from the French network on inherited platelet disorders.

Latger-Cannard V, Philippe C, Bouquet A, Baccini V, Alessi MC, Ankri A, Bauters A, Bayart S, Cornillet-Lefebvre P, Daliphard S, Mozziconacci MJ, Renneville A, Ballerini P, Leverger G, Sobol H, Jonveaux P, Preudhomme C, Nurden P, Lecompte T, Favier R.

Orphanet J Rare Dis. 2016 Apr 26;11:49. doi: 10.1186/s13023-016-0432-0.

47.

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.

Berthon C, Raffoux E, Thomas X, Vey N, Gomez-Roca C, Yee K, Taussig DC, Rezai K, Roumier C, Herait P, Kahatt C, Quesnel B, Michallet M, Recher C, Lokiec F, Preudhomme C, Dombret H.

Lancet Haematol. 2016 Apr;3(4):e186-95. doi: 10.1016/S2352-3026(15)00247-1. Epub 2016 Mar 18.

PMID:
27063977
48.

Comprehensive mutational profiling of core binding factor acute myeloid leukemia.

Duployez N, Marceau-Renaut A, Boissel N, Petit A, Bucci M, Geffroy S, Lapillonne H, Renneville A, Ragu C, Figeac M, Celli-Lebras K, Lacombe C, Micol JB, Abdel-Wahab O, Cornillet P, Ifrah N, Dombret H, Leverger G, Jourdan E, Preudhomme C.

Blood. 2016 May 19;127(20):2451-9. doi: 10.1182/blood-2015-12-688705. Epub 2016 Mar 15.

49.

Acquisition of genomic events leading to lymphoblastic transformation in a rare case of myeloproliferative neoplasm with BCR-JAK2 fusion transcript.

Duployez N, Nibourel O, Ducourneau B, Grardel N, Boyer T, Bories C, Darre S, Coiteux V, Berthon C, Preudhomme C, Roche-Lestienne C.

Eur J Haematol. 2016 Oct;97(4):399-402. doi: 10.1111/ejh.12752. Epub 2016 Mar 26.

PMID:
26935241
50.

The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia.

Olombel G, Guerin E, Guy J, Perrot JY, Dumezy F, de Labarthe A, Bastie JN, Legrand O, Raffoux E, Plesa A, Wagner-Ballon O, Cornet E, Salaun V, Preudhomme C, Thomas X, Pautas C, Chantepie S, Turlure P, Castaigne S, Dombret H, Feuillard J.

Blood. 2016 Apr 28;127(17):2157-60. doi: 10.1182/blood-2016-01-689976. Epub 2016 Feb 29. No abstract available.

Supplemental Content

Loading ...
Support Center